Sign in
FI

FLOTEK INDUSTRIES INC/CN/ (FTK)·Q4 2024 Earnings Summary

Executive Summary

  • Strongest quarter of 2024 across all key metrics: revenue $50.758M (+20% YoY), gross margin 24.2% (approx.), net income $4.429M, diluted EPS $0.14, and adjusted EBITDA $7.023M; full-year adjusted EBITDA $20.327M exceeded raised guidance ($16.5–$18.5M) by ~10% .
  • Mix and cost actions drove upside: sequential margin expansion came from a surge in external chemistry, a 67% sequential rise in Data Analytics service revenue, and the order shortfall penalty under the long‑term ProFrac supply agreement .
  • Data Analytics momentum and “Measure More” strategy (VeraCal flare monitoring, XSPCT custody transfer, JP3 Raman) increased recurring service mix; 13 VeraCal units in rental service, 14 XSPCT pilots, and 15 power generation units deployed in Q4, with $1.3M flare revenue in 2H24 .
  • 2025 guidance will be issued with Q1 results; near‑term catalysts include DaaS ramp, international chemistry wins (Saudi, UAE), and regulatory-driven flare monitoring adoption offsetting North America frac slowdown seasonality .

What Went Well and What Went Wrong

  • What Went Well

    • Record external customer activity and international traction: external chemistry +50% QoQ; international chemistry ~$4.5M in Q4 (largest in a decade) with Saudi slickwater approval and UAE/ADNOC projects, lifting mix and margins .
    • Data Analytics services scaled: service revenue +124% YoY; 13 VeraCal rental units, 14 XSPCT pilots, 15 power gen units deployed; $1.3M flare revenue in final 5 months of 2024, underpinning recurring revenue .
    • Cost discipline and mix drove profitability: gross margin improved 600 bps sequentially; SG&A fell 11% for FY24 (17% ex‑stock comp); debt/Adj. EBITDA improved to 0.2x with ABL undrawn post‑year‑end .

  • What Went Wrong

    • North America upstream softness: active frac fleets declined >25% from the Q1 peak, pressuring broader market demand even as FTK gained share .
    • Regulatory timing friction: EPA flare rule amendments in December extended the comment period and slowed some flare activity, delaying parts of the ramp despite long‑term opportunity .
    • Full‑year revenue modestly down YoY ($187.025M vs $188.058M) despite strong Q4; growth skewed to profitability over top‑line given related‑party volumes tied to natural gas markets .

Financial Results

Overall performance vs prior periods (oldest → newest):

MetricQ4 2023Q2 2024Q3 2024Q4 2024
Revenue ($USD Millions)$42.188 $46.152 $49.742 $50.758
Gross Profit ($USD Millions)$9.430 $9.170 $9.119 $12.277
Gross Margin % (calc)22.4% (calc from )19.9% (calc from )18.3% (calc from )24.2% (calc from )
Net Income ($USD Millions)$2.104 $1.974 $2.532 $4.429
Diluted EPS ($)$0.07 $0.06 $0.08 $0.14
Adjusted EBITDA ($USD Millions, Non‑GAAP)$3.952 $4.439 $4.840 $7.023

Q4 2024 segment revenue breakdown (YoY):

SegmentQ4 2023 ($MM)Q4 2024 ($MM)
Chemistry Technologies – External$17.996 $21.071
Chemistry Technologies – Related Party$22.769 $27.215
Chemistry Technologies – Total$40.765 $48.286
Data Analytics – Product$0.688 $0.826
Data Analytics – Service$0.735 $1.646
Data Analytics – Total$1.423 $2.472

Select Q4 2024 KPIs:

KPIQ4 2023Q4 2024
Revenue from external customers ($MM)$19.239 $23.328
Data Analytics service revenue ($MM)$0.735 $1.646
International chemistry revenue ($MM)—~$4.5 (approx., call disclosure)
ProFrac minimum purchase recognized ($MM)—$8.600

Non‑GAAP reconciliation highlights (Q4 2024): Adjusted EBITDA excludes items including stock comp $0.451M, amortization of contract asset $1.271M; EBITDA (GAAP) was $5.267M before these adjustments .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Adjusted EBITDA (Non‑GAAP)FY 2024$14–$18M (raised Aug 6, 2024) $16.5–$18.5M (raised Nov 4, 2024) Raised
Adjusted Gross Profit Margin % (Non‑GAAP)FY 202418–22% (original) 20–22% (Nov 4, 2024) Raised
2025 GuidanceFY 2025To be issued with Q1 results (practice) Will be issued with Q1 2025 results Maintained (timing)

Note: FTK ultimately delivered FY24 adjusted EBITDA of $20.327M and a 21% gross profit margin, exceeding the raised ranges (performance, not guidance) .

Earnings Call Themes & Trends

TopicPrevious Mentions (Q2 & Q3 2024)Current Period (Q4 2024)Trend
Data Analytics (DaaS/service mix)EPA approved JP3 for flare (Jul); DA revenue +22% QoQ in Q2; +30% QoQ in Q3; flare 25% of Q3 DA revenue; 15 flare tests by 9/30 .Service = 67% of DA revenue; 13 VeraCal rentals, 14 XSPCT pilots, 15 power gen units; $1.3M flare revenue in 2H24; recurring model emphasized .Accelerating recurring mix and deployments.
International chemistryLimited detail in Q2/Q3 disclosures.~$4.5M Q4 international revenue; Saudi slickwater approval; ADNOC/UAE projects; Oman activity; higher-margin specialty mix .Expanding, higher‑margin contribution.
Regulatory (EPA flare rules)JP3 first approved alt method; $220M upstream TAM cited .Dec‑20 proposed amendments caused some delay, but TAM intact; customers continue adoption .Regulatory clarity improving; demand building despite timing.
Macro/market (frac fleets, LNG)Q3 commentary: gaining share in contracting NA market .NA frac fleets down >25% from Q1 peak; management cautiously optimistic; bullish on gas/LNG and power gen opportunities .Mixed macro; gas‑levered tailwinds.
Working capital/liquidityABL upsized to $20M in Aug; borrowings down 81% by Q3 .YE ABL $4.8M drawn; now nothing drawn; debt/Adj. EBITDA 0.2x; Q1 AR tailwind from OSP collection expected .Strengthening balance sheet and cash conversion.

Management Commentary

  • “Q4 2024 total revenues rose 20% versus Q4 2023… external customer revenue [was] the highest in the last 5 years… international chemistry [made] its largest quarterly contribution in the last 10 years.” – CEO Ryan Ezell .
  • “Fourth quarter gross profit increased 35% sequentially… driven by [external chemistry], a 67% sequential increase in Data Analytics service revenue, and [the] order shortfall penalty under our long‑term supply agreement.” – CFO Bond Clement .
  • “We grew VeraCaL rental units to 13… sold an additional 2… generated over $1.3 million in the final 5 months of 2024… 14 [XSPCT] committed units… 15 active power generation units… 100%… monthly subscriptions.” – CEO Ryan Ezell .
  • “We achieved the highest profitability metrics in nearly a decade… expanded our technology portfolio with VeraCal, JP3 Raman, and XSPCT… driving high‑margin growth into 2025 and beyond.” – CEO Ryan Ezell (press release) .

Q&A Highlights

  • International growth and margins: ~$4.5M Q4 international chemistry (UAE ~$7.4M FY); Saudi/UAE specialty products support higher margins vs commodity friction reducers .
  • Regulatory outlook: EPA amendments extended comment window and slowed some activity, but major operators continue rollouts; additional VeraCal units being added; management expects ongoing monitoring demand .
  • Seasonality and Q1 setup: International should smooth typical Q1 lumpiness; NA activity picking up into March vs prior Q1s .
  • DA pilots and revenue conversion: 45‑day pilot periods transition to multi‑year service contracts; first pilot cohorts start revenue late Q1 to Q2 2025 .
  • Cash/Capex: Expect Q1 working capital tailwind from OSP sale; DA CapEx to rise in 2025 but manageable relative to OSP collections .

Estimates Context

  • Wall Street consensus for Q4 2024 EPS and revenue via S&P Global was not available at the time of this analysis; as a result, estimate comparisons are omitted.
  • Management did not provide 2025 guidance; consistent with prior years, FTK will issue guidance alongside Q1 2025 results .

Key Takeaways for Investors

  • Q4 demonstrated operating leverage: revenue mix (external chemistry + DA services) and cost actions drove a sharp margin inflection to ~24%, with adjusted EBITDA up 46% sequentially and 78% YoY .
  • Recurring DaaS runway: rapid deployment of VeraCal/XSPCT/power gen under subscription contracts provides higher‑quality revenue and visibility into 2025+ .
  • International is a material swing factor: approvals and projects in Saudi/UAE/Oman added ~$4.5M in Q4 and skew margins higher given specialty mix .
  • Structural support from ProFrac agreement: Q4 included $8.6M from minimum purchase requirements; OSP collection should aid Q1 working capital and liquidity .
  • Balance sheet improved: debt/Adj. EBITDA down to 0.2x and ABL currently undrawn, providing flexibility to fund DA growth .
  • Watch near‑term risks: NA seasonality in Q1, regulatory timing on EPA amendments, and commodity‑driven customer budget shifts; management is “cautiously optimistic” for early 2025 .
  • Near‑term catalysts: DaaS conversions from pilots in 1H25, international order flow, and the 2025 guidance issuance with Q1 results .

Appendix: Actuals vs Consensus (Q4 2024)

MetricActualS&P Global ConsensusSurprise
Revenue$50.758M N/AN/A
Diluted EPS$0.14 N/AN/A
Adjusted EBITDA (Non‑GAAP)$7.023M N/AN/A

All financial and operational data are sourced from FTK’s Q4 2024 press release, 8‑K exhibits, investor presentation, and the Q4 2024 earnings call transcript as cited above. Non‑GAAP metrics and adjustments are per company disclosures and reconciliations in the referenced documents .